- JP-listed companies
- J-Pharma Co.,Ltd.
- Income statement
J-Pharma Co.,Ltd. (520A) Income statement
Market cap
¥10.5B
P/E ratio
J-Pharma develops innovative small-molecule drugs targeting LAT1 transporters to treat cancer and autoimmune diseases with novel mechanisms of action.
| 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Operating income | - | - | - | -1,723 | -1,596 |
| Income before tax | -931 | -1,077 | -1,087 | -1,640 | -1,527 |
| Provision for income taxes | - | - | - | 1 | 1 |
| Effective tax rate (%) | - | - | - | ||
| Net income | -932 | -1,081 | -1,098 | -1,652 | -1,499 |
| Earnings per share | -1,190.1 | -974.48 | -952.74 | -263.57 | -184.05 |
| EBITDA | - | - | - |